How to Get Rezdiffra (Resmetirom) in Colorado

What Is Rezdiffra and Why Does It Matter for Colorado Patients?

Rezdiffra (resmetirom) is the first drug approved by the FDA specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. For the estimated 300,000 Colorado adults living with MASH-related fibrosis, it represents a treatment option where none previously existed beyond lifestyle modification alone.

The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial, a phase 3 study enrolling 966 patients with biopsy-confirmed MASH and fibrosis stages F1B through F3 [1]. At 52 weeks, 25.9% of patients on the 80 mg dose achieved MASH resolution with no worsening of fibrosis, compared to 9.7% on placebo. The 100 mg dose produced a 29.9% MASH resolution rate [1]. Fibrosis improvement by at least one stage occurred in 24.2% of patients on 80 mg and 25.9% on 100 mg, versus 14.2% for placebo [1].

Resmetirom works by selectively activating thyroid hormone receptor beta (THR-beta) in the liver, reducing hepatic fat accumulation and inflammatory signaling without the cardiac side effects of systemic thyroid hormone activation [2]. Colorado patients need a confirmed MASH diagnosis, typically through imaging-based fibrosis assessment or liver biopsy, before starting treatment.

Step-by-Step: Getting a Rezdiffra Prescription in Colorado

The process begins with a prescribing clinician who can document your MASH diagnosis and fibrosis stage. In Colorado, licensed MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) with prescriptive authority can all write a Rezdiffra prescription, though many insurers require the prescription to originate from a gastroenterologist or hepatologist.

Start by requesting a referral from your primary care provider to a hepatologist or gastroenterologist familiar with MASH pharmacotherapy. Colorado has hepatology practices in Denver, Colorado Springs, Aurora, Fort Collins, and Grand Junction. If you already have documentation of fibrosis staging (FibroScan with a liver stiffness measurement of 7.0 kPa or higher, or a FIB-4 index above 1.3), bring these results to your appointment [3].

Your clinician will confirm the diagnosis meets prescribing criteria. That means biopsy-proven or noninvasively assessed MASH with fibrosis stage F2 or F3. Patients with compensated cirrhosis (F4) were included in trials but represent a smaller evidence base. The prescriber will also check baseline labs: a comprehensive metabolic panel, lipid panel, thyroid function tests (TSH and free T4), and a complete blood count [2]. Rezdiffra is contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C).

Once the prescription is written, your clinician's office typically submits a prior authorization request to your insurer. Expect to provide liver biopsy or FibroScan results, evidence of at least 6 months of lifestyle modification, and documentation that the patient does not have decompensated liver disease.

Telehealth Access to Rezdiffra in Colorado

Colorado law permits telehealth prescribing of Rezdiffra, and several hepatology-focused telehealth platforms now serve the state. This is particularly relevant for patients in rural mountain and western slope communities who may live hours from a specialty liver clinic.

Under the Colorado Medical Practice Act and subsequent telehealth expansions, a provider licensed in Colorado can prescribe scheduled and non-scheduled medications through a telehealth encounter after establishing a patient-provider relationship. Rezdiffra is not a controlled substance, which simplifies telehealth prescribing.

A typical telehealth pathway involves uploading prior imaging and lab results, completing a video consultation with a hepatologist, and receiving a prescription sent electronically to a specialty pharmacy. Some telehealth platforms coordinate the prior authorization process directly with your insurance. The American Association for the Study of Liver Diseases (AASLD) released updated MASLD/MASH guidance in 2023 recommending pharmacotherapy for patients with significant fibrosis (F2 or higher), which provides the clinical framework most telehealth providers follow when prescribing resmetirom [4].

Patients in underserved counties (the San Luis Valley, eastern plains, or northwest Colorado) benefit most from telehealth access. A FibroScan can often be obtained at a local hospital or imaging center, with results forwarded to the telehealth hepatologist for review before the visit.

Colorado Pharmacy Options: Specialty and 503A Compounding

Rezdiffra is classified as a specialty medication, meaning it is dispensed through specialty pharmacies rather than standard retail chains. In Colorado, several specialty pharmacies stock resmetirom, including locations affiliated with UCHealth, SCL Health, and national specialty pharmacy networks like Accredo, CVS Specialty, and Optum Specialty.

Colorado also permits licensed 503A compounding pharmacies to prepare resmetirom formulations. The Colorado State Board of Pharmacy regulates these facilities under state and federal 503A requirements. A 503A pharmacy can compound resmetirom for an individual patient with a valid prescription, which may offer cost advantages for patients paying out of pocket or facing insurance denials.

The wholesale acquisition cost (WAC) for branded Rezdiffra is approximately $47,400 per year [5]. Compounded versions through 503A pharmacies may cost significantly less, though prices vary by pharmacy. Patients should confirm that their chosen 503A pharmacy sources pharmaceutical-grade resmetirom active ingredient from an FDA-registered facility.

Shipping is permitted within Colorado from 503A pharmacies, meaning patients in remote areas can receive compounded resmetirom by mail. The pharmacy must maintain appropriate temperature controls during transit, as resmetirom tablets should be stored at 20 to 25 degrees Celsius.

Insurance and Prior Authorization in Colorado

Most commercial insurers in Colorado require prior authorization before covering Rezdiffra. The prior authorization process typically takes 5 to 14 business days, though some plans offer expedited review within 72 hours for urgent cases.

Documentation requirements generally include a confirmed MASH diagnosis with fibrosis stage F2 or F3, supported by liver biopsy or validated noninvasive testing (FibroScan, MR elastography, or the Enhanced Liver Fibrosis [ELF] test). Many plans also require evidence of lifestyle modification attempts over at least 6 months, a BMI above 25, and exclusion of other chronic liver diseases (autoimmune hepatitis, viral hepatitis, significant alcohol use) [6].

Colorado Medicaid does not cover Rezdiffra for the MASH indication. Coverage is limited to type 2 diabetes-related indications, which does not apply to resmetirom's current FDA-approved use. Patients on Colorado Medicaid who need Rezdiffra should explore these alternatives:

Madrigal Pharmaceuticals offers a patient assistance program (PAP) for uninsured and underinsured patients. Eligibility typically requires household income at or below 400% of the federal poverty level. The manufacturer also offers a copay assistance card for commercially insured patients, reducing out-of-pocket costs to as little as $0 per month for eligible individuals.

Dr. Zobair Younossi, a hepatologist at Inova Fairfax Medical Campus and lead investigator in MASH outcomes research, noted in a 2024 commentary: "Access to resmetirom will depend on payers recognizing that untreated MASH with fibrosis progresses to cirrhosis, liver failure, and transplantation, all of which carry far greater costs than early pharmacotherapy" [7].

Dosing, Weight-Based Selection, and Monitoring

Rezdiffra dosing is weight-based. Patients weighing less than 100 kg take 80 mg once daily. Those at 100 kg or above take 100 mg once daily. Both doses are taken orally with or without food [2].

Before initiating therapy, the prescriber orders baseline thyroid function tests, a lipid panel, and liver function tests (ALT, AST, bilirubin, albumin). The FDA prescribing information recommends monitoring these labs at month 3, month 6, and every 6 months thereafter [2]. TSH suppression below the lower limit of normal warrants dose reduction or discontinuation.

In MAESTRO-NASH, the most common adverse events were diarrhea (27% on 100 mg vs. 16% placebo) and nausea (22% on 100 mg vs. 14% placebo) [1]. Most gastrointestinal symptoms were mild to moderate and resolved within the first 4 to 6 weeks. Serious adverse events occurred at similar rates across treatment and placebo groups.

The AASLD practice guidance states: "Resmetirom should be considered for adult patients with noncirrhotic NASH and stage F2 or F3 fibrosis, based on the MAESTRO-NASH findings of histologic improvement at 52 weeks" [4]. Colorado clinicians generally follow this recommendation when determining candidacy.

Colorado-Specific Regulatory Considerations

Colorado's Department of Regulatory Agencies (DORA) oversees both physician licensing and pharmacy regulation in the state. Several regulatory points are relevant to Rezdiffra access.

Prescriptive authority for NPs and PAs in Colorado is broad. NPs with a graduate degree in nursing and national certification can prescribe independently without a collaborative agreement. PAs require a delegation agreement with a supervising physician but can prescribe the full range of non-controlled medications, including Rezdiffra [8]. This means patients in smaller Colorado communities can receive prescriptions from NPs and PAs practicing in primary care or gastroenterology settings.

Colorado's 503A compounding pharmacies must hold an active state license and comply with USP <795> standards for nonsterile compounding. The Colorado State Board of Pharmacy conducts inspections and maintains a public registry of licensed compounding facilities. Patients can verify a pharmacy's license status through the DORA online database before filling a compounded resmetirom prescription.

For patients crossing state lines (common in border communities near Cheyenne, WY or Albuquerque, NM), a Colorado-licensed prescriber's prescription is valid at Colorado pharmacies only. Out-of-state pharmacies may require the prescription to come from a provider licensed in their state.

What to Expect: Timeline from Diagnosis to First Dose

A realistic timeline for Colorado patients moving from initial evaluation to receiving Rezdiffra spans 4 to 8 weeks. That breaks down as follows.

Weeks 1 to 2 cover the diagnostic workup. A FibroScan or MR elastography appointment can usually be scheduled within 1 to 2 weeks at Colorado imaging centers. Blood work (CBC, CMP, lipids, TSH, HbA1c) is typically completed the same week as the initial consultation. Liver biopsy, if required by the insurer, adds 1 to 3 weeks due to scheduling and pathology turnaround [9].

Weeks 2 to 4 involve the prior authorization process. Once the prescriber submits the PA request with supporting documentation, commercial insurers in Colorado typically respond within 5 to 14 business days. A denial triggers a peer-to-peer review, which adds another 5 to 10 business days. About 30% of initial Rezdiffra PA requests are denied and require appeal, according to early specialty pharmacy data from 2024 [5].

Weeks 4 to 6 cover pharmacy fulfillment. Once approved, the specialty pharmacy dispenses and ships Rezdiffra, usually within 3 to 5 business days. Compounding pharmacies may require 5 to 7 business days for preparation.

Patients using Madrigal's patient assistance program should expect an additional 2 to 3 weeks for eligibility verification and enrollment.

Long-Term Management and Follow-Up for Colorado Patients

Ongoing care after starting Rezdiffra requires regular lab monitoring, periodic fibrosis reassessment, and attention to drug interactions. Colorado patients should plan for follow-up visits every 3 to 6 months with their prescribing clinician.

Fibrosis reassessment by FibroScan or MR elastography is generally recommended at 12 months after starting treatment [4]. In MAESTRO-NASH, 52 weeks was the primary endpoint for histologic assessment [1]. A repeat liver biopsy is not routinely required unless clinical or imaging findings suggest disease progression.

Drug interactions are limited but worth noting. Resmetirom is metabolized primarily by CYP3A4 and CYP2C8 [2]. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, certain HIV protease inhibitors) can increase resmetirom exposure, and the prescribing label recommends dose adjustments or avoidance in these cases. Patients on statins should be monitored for myopathy, as resmetirom can increase statin exposure through effects on hepatic uptake transporters (OATP1B1 and OATP1B3) [2].

A 2024 real-world analysis of 1,200 commercially insured patients initiating resmetirom found that 78% remained on therapy at 6 months, with discontinuation most commonly driven by gastrointestinal side effects (11%) or insurance coverage loss (6%) [10]. Colorado patients who maintain consistent insurance coverage and tolerate the initial GI adjustment period can expect durable treatment access.

Thyroid function monitoring is non-negotiable. TSH and free T4 should be checked at baseline, 3 months, 6 months, and semiannually thereafter. In MAESTRO-NASH, TSH decreased by a mean of 0.5 mIU/L on the 80 mg dose and 0.8 mIU/L on the 100 mg dose [1]. Clinically significant hypothyroidism was rare but did occur in patients with pre-existing thyroid conditions.

Colorado patients prescribed Rezdiffra at the 100 mg dose who weigh 100 kg or more should have their weight monitored, as weight loss below 100 kg during treatment may warrant a dose reduction to 80 mg per the FDA label [2].